Controlling how many cells make a fly by Moore, Pete
In our earliest biology lessons we
learnt that all living organisms grow,
and that growth requires an increase in
both cell number and cell size. But
how is this controlled? Insulin  and
insulin-like growth factors (IGFs; see
the ‘Background’ box) play a critical
role, and they are also implicated in
medical conditions such as cancer
and diabetes. So understanding their
mechanism of action at the molecular
level will have important conse-
quences not only for our knowledge of
biology, but for pathology as well.
Working at the University of Zürich,
Switzerland, Ernst Hafen heads a team
that is looking at the control of growth.
“You can think of our work in terms of
a triangle,” he explains. “At the three
corners are Homo sapiens, Caenorhabditis
elegans and Drosophila melanogaster, and
at the center of the triangle is the
insulin-signaling pathway.” Hafen’s
team has learnt important lessons
about the pathway from each species,
and their new findings, published in
this issue of Journal of Biology [1], add
significant evidence in support of the
idea that the key functions of the
pathway have been powerfully con-
served through evolution. The new
results also serve to tie together con-
trols of cell size and cell number with
how organisms respond to oxidative
stress and nutrient availability (see
‘The bottom line’ box for a summary
of their work).
Insulin and IGF in mammals
“We know most of the biochemistry of
the system from mammalian cell-
culture experiments and knockout
mice,” explains Martin Jünger, a PhD
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The bottom line
• The homologous transcription factors FOXO and DAF-16 are known
to lie on the insulin-signaling pathway, but it was unclear precisely how
this pathway regulates cell size, cell number, and development in dif-
ferent organisms.
• In Drosophila, FOXO mutants have no growth phenotype, but are more
sensitive than wild-type flies to oxidative stress. 
• Mutations in chico, an upstream component of the insulin-signaling
pathway, reduce both cell size and cell number; an additional FOXO
mutation rescues the reduction in cell number, indicating that wild-
type FOXO negatively regulates this aspect of growth. But a FOXO-
chico double mutant still has its cell size reduced.
• Cell size is regulated by the S6 kinase branch of the insulin-signaling
pathway, while FOXO regulates cell number, in part by up-regulating a
protein involved in the regulation of translation.
• The insulin-signaling pathway is highly conserved in mammals,
C. elegans and Drosophila, and may have evolved in the ancestor of
metazoans to allow regulation of growth and development in response
to stress and nutrient availability.student in Hafen’s lab. Decades of
experiments have shown that insulin
regulates energy metabolism, and
more recent results show that it plays a
key role in embryonic [2] and post-
embryonic [3] growth, as well as the
determination of lifespan [4]. 
Studies in mammalian cells have
also shown that insulin negatively reg-
ulates FOXO (Forkhead box, subclass
O)  transcription factors, which in
turn arrest the cell cycle and, in some
types of cell, induce cell death. FOXO
transcription factors therefore have a
negative influence on growth, and
their function is turned off by the
insulin effector protein kinase B (PKB,
which is also known as AKT [5]). 
The worm and its dauer stage
The link between insulin and FOXO
proteins initially came from experi-
ments in C. elegans, where insulin
signals to the FOXO equivalent, DAF-
16 (see Table 1 for the names of corre-
sponding proteins in the different
species discussed in this article). In
worms, the effect of modulating the
insulin-signaling pathway is quite
unique: rather than affecting size, it
induces a change in the nematode’s
developmental program. Adverse con-
ditions, such as starvation, decrease
signaling activity within the pathway,
which in turn drives the worms into
the developmentally arrested ‘dauer
stage’ (DAF denotes ‘dauer forma-
tion’). Dauer larvae alter their metabo-
lism, stockpile fat and can survive in
this state for at least four to eight times
longer than the normal two-week life-
span of C. elegans. 
The evidence that dauer formation
is dependent on the transcription
factor DAF-16 comes from genetic
experiments showing that if the
insulin-signaling pathway is mutated,
C. elegans enters the dauer stage. But in
a double mutant in which DAF-16 is
also disabled, the worms develop as
normal. The clear implication is that in
normal animals the insulin pathway
has its effects on dauer formation via
negative regulation of DAF-16. “But the
link to growth [in worms] is not clear,”
says Hafen. “Because this strange worm
is built by a precisely fixed number of
cells, there is no relation between body
size and insulin signaling.” This appar-
ent difference in action threw into
question the idea that the insulin
pathway has a conserved role in
worms and mammals.
Drosophila and growth
Into this arena of confusion comes
Drosophila. The clearest indication of
the way that insulin signaling affects this
species comes from the so-called chico
mutant. Wild-type Chico protein func-
tions in the insulin-signaling pathway,
and flies lacking it are small with
delayed development. In many ways
this is similar to the situation in
mammals, where mutations in the
insulin/IGF pathway affect growth and
body size. The flies have fewer cells,
and the cells they do have are smaller
in size. “This [growth] reduction is
something that was never seen in
C. elegans,” says Hafen. “So, before our
recent work, the best concept was that
the initial pathway was the same in all
species, but the readout was different,”
leading to growth in mammals but pre-
venting dauer formation in C. elegans.
Sorting out size and number
The insulin-signaling pathway is nor-
mally triggered by insulin binding to the
insulin receptor, which then phospho-
rylates Chico, an intracellular adapter
protein (see Figure 1). Chico then
recruits the phosphatidylinositol (PI)
3-kinase, which in turn phosphorylates
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Background
• Both insulin, first identified for its role in energy metabolism, and
insulin-like growth factors (IGFs) signal through the insulin
receptor, a transmembrane protein kinase that initiates a signaling
cascade that includes transcriptional regulation by FOXO, a member
of the Forkhead family of transcription factors.
• The insulin-signaling pathway has roles in growth and development
in many animal species, and is implicated in the control of lifespan, ini-
tially from studies of the genes controlling the formation of the devel-
opmentally arrested, stress-resistant dauer form in C. elegans.
• Protein kinase B (PKB, also known as AKT) phosphorylates FOXO
and turns off its transcriptional activity. PKB also regulates growth
through a pathway independent of FOXO but including the S6 kinase. 
Table 1
Terms for equivalent proteins in different species
Human C. elegans Drosophila
Forkhead transcription factors Three different  DAF-16 dFOXO
hFOXO proteins
Insulin effector kinases,  PDK1 and  PDK1, Akt -1  dPDK1 and 
containing pleckstrin  PKB/AKT 1-3 and Akt-2 dPKB/dAktfs
homology (PH) domains
Journal of Biology 2003, 2:16the membrane-bound phospholipid
phosphatidylinositol (4,5)-bisphos-
phate (PIP2) to phosphatidylinositol
(3,4,5)-trisphosphate (PIP3). Hafen
explains that the next key event is that
PIP3 causes kinases like PDK1 and
PKB, which contain plekstrin-homol-
ogy (PH) domains, to be translocated
from the cytoplasm to the membrane.
Now, Jünger, Hafen and colleagues
have looked at what happens in
Drosophila downstream of PKB [1] (see
the ‘Behind the scenes’ box for more
discussion of the background to the
work). From work in mammalian cells,
they knew that PKB phosphorylates
transcription factors of the FOXO
family, causing them to leave the
nucleus and become trapped in the
cytoplasm where they cannot stimulate
the initiation of transcription of target
genes. “In C. elegans, we know that this
[part of the pathway] influences devel-
opment, not size, so the question for
us was if size was mediated through
DAF-16 in flies.”
One part of the answer to this
question - dealing with the size of
each cell - came from a paper previ-
ously published in Science [6]. This
showed that cell size is controlled in
Drosophila by the S6 kinase (dS6K),
an enzyme that apparently acts down-
stream of dPDK1 and dPKB and is
named for its effects on ribosomal
protein S6. Mutating dS6K produces
small flies that have the same number
of cells as in the wild type but whose
cells are small. The answer to the cell
number question came from the
paper by Jünger et al. [1], which ini-
tially set out to characterize the fly
DAF-16 homolog and to assess both
whether and how it fitted into the fly
insulin-signaling pathway and also its
growth-modulating capabilities.
When the Zürich team produced
dFOXO mutants they were initially sur-
prised. The flies were viable and
normal-sized; there was no apparent
phenotype, other than that the flies
were more susceptible to oxidative
stress than were their wild-type
cousins. Jünger and colleagues had
anticipated that removing the pre-
sumed negative influence would cause
the flies to grow bigger. At first, they
questioned whether they really had
mutated dFOXO, but the genetic and
molecular evidence was compelling.
As a next step, Jünger started to test
the mutants in a genetic background in
which other aspects of the insulin
pathway were compromised. In this
case, a normal fly would produce
fewer, smaller cells. But take dFOXO
away and the flies have small cells, but
almost the normal number. “The
reduced cell number [in insulin-
pathway mutants] is rescued by the
absence of the transcription factor,
because [wild-type] dFOXO has a neg-
ative influence,” he explains. 
Jünger went on to show that
dFOXO operates in part by up-regulat-
ing the gene for a binding protein
called d4E-BP. With larger quantities of
this binding protein produced, the
translation-initiation factor eIF4E is
effectively removed from the transla-
tion machinery, in turn inhibiting the
initiation of protein synthesis. This
shows that insulin operates not only by
regulating pre-existing 4E-BP protein
via phosphorylation [7], but also by
influencing the intracellular abundance
of 4E-BP at the gene expression level. 
“We have shown that d4E-BP is a
relevant target [of the pathway],”
says Jünger, “but we absolutely don’t
postulate that it is the only one.
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Figure 1
The key molecules of the insulin-signaling pathway, as discussed in the text. 
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PDK1 PKBIt’s more like a ‘proof-of-principle’
experiment, showing that we can
find physiologically relevant targets
in our rather artificial cell culture
system, where we stimulate Drosophila
cultured cells with bovine insulin! But
recent microarray studies (by Puig et
al. [8] and Ramaswamy et al. [9])
suggest that FOXO proteins work by
modulating the transcription of large
sets of target genes.” 
The picture that emerges for
Drosophila is that the insulin signaling
pathway forks at PKB, with an S6K
element controlling cell size, and a
FOXO element taking charge of cell
number (see Figure 1).
Related studies
At the same time as the Jünger et al.
paper [1] was published, two other
groups were publishing findings that
support the same idea. Robert Tjian
and colleagues at the University of Cal-
ifornia, Berkeley, presented biochemi-
cal evidence that when insulin is
applied, dFOXO is phosphorylated by
dPKB, leading to it being retained in
the cytoplasm and therefore not being
capable of initiating transcription [8].
His group reports that “targeted expres-
sion of dFOXO in fly tissues regulates
organ size by specifying cell number
with no effect on cell size”. Moreover,
they also found and validated d4E-BP
as a target gene. This nicely comple-
ments the findings of Jünger et al. [1].
On top of this, Tjian’s group had
another striking result. “We found that
FOXO also regulates expression of the
insulin receptor,” says Tjian. “This
means that in the absence of insulin,
FOXO is produced. This not only
limits growth, but it also up-regulates
sensitivity for insulin. The system is
now primed to look for lower concen-
trations of insulin.”
A third study, by Jamie Kramer and
colleagues at the Memorial University
of Newfoundland, Canada, presents a
slightly different picture. Kramer et al.
[10] agree with Jünger et al. and
Tjian’s group that dFOXO is the fly
homolog of DAF-16 and hFOXO (see
Table 1). But, in a key difference,
Kramer  et al. found that overexpres-
sion of dFOXO leads to reductions in
both cell size and cell number. “We
have seen this effect in both the eye
and the wing of Drosophila,” says
Kramer.  He believes that this differ-
ence between his results and those of
the other groups is most likely to
arrive from his use of overexpression
analysis whereas Jünger used loss-of-
function techniques.
“A general problem,” agrees Jünger,
“is that overexpression studies are
prone to artefacts, because over-
expressed proteins often start doing
things which under normal, physiolog-
ical protein concentrations they do
not.” Tjian agrees; “If I got results from
overexpression experiments that differ
from loss-of-function work I would be
inclined to trust the loss-of-function
study,” he says. At the same time, Tjian
points out that his team’s findings also
came from overexpression studies. He
is now keen to study the exact differ-
ences in method between his own and
Kramer’s work to see if this sheds light
on the differences.
16.4 Journal of Biology 2003, Volume 2, Issue 3, Article 16 Moore http://jbiol.com/content/2/3/16
Journal of Biology 2003, 2:16
Behind the scenes
Journal of Biology asked Martin Jünger about how and why he set out to study
dFOXO and its role in regulating growth.
What prompted the work?
Team members in the lab had a long-running interest in growth regulation
and had performed extensive genetic screens for growth-affecting muta-
tions. They had found many components of the insulin-signaling cascade,
but did not find FOXO. As FOXO is such an established target in
mammals and worms, it was an obvious issue to address. 
My involvement started with my PhD thesis. I got my degree in bio-
chemistry in Berlin and became interested in signal transduction during my
diploma work. I moved to Ernst’s lab for the beginning of my thesis to
combine signal transduction and genetics.
How long did it take to do the experiments, and what was the
team’s reaction to the results?
“In total it took about three years, although when I started in December
2000, several months work had already been invested by Michael Green-
berg’s team at Harvard. [When we saw the results] we were surprised
and excited, mainly because of FOXO’s double role, the absence of a
growth phenotype and the effect within the mutant context - it was a very
interesting project.
What are the next steps?
We will certainly follow up on some of the results, for example the oxida-
tive stress issue and the control of cell proliferation. More extensive
expression-profiling studies should help to clarify the molecular mecha-
nisms underlying these effects. The rather small microarray experiment in
our dFOXO paper was something of a sidetrack. 
Personally, I will invest much of my time in studying the insulin
pathway in cultured cells in more detail at the transcriptome and pro-
teome level. We have a couple of exciting collaborations going on.Completing the triangle
For Hafen, the new data complete the
triangle. “In the worm, fly and human,
FOXO is [a] negative [regulator of
growth],” he says. “Now the pictures do
not look different at all. What we see is a
great underlying evolutionary conserva-
tion of this pathway.” In Hafen’s view,
this pathway governs one of the most
fundamental controls that the ancestors
of multicellular organisms had to
evolve. “Wild flies are not like our labo-
ratory flies, fed on delicious food day in,
day out. In nature animals often have
too little food, so they have to evolve
mechanisms to deal with the issue. They
can’t just run their metabolism at
maximal speed, irrespective of whether
there is food around or not; they have to
find ways to adjust their metabolic rate
and their speed of development accord-
ing to the availability of nutrients.”
He postulates that his group didn’t
see the full effect of the dFOXO
mutants because the flies were growing
in unnatural conditions: because the
flies are fed the whole time, the insulin
pathway is constantly activated. A con-
stantly starving wild fly with a dFOXO
mutation might have an impaired
ability to limit its rate of growth to suit
the nutrient availability.
Hafen likens the situation to driving
a car when you know that the tank is
running out of fuel. “You don’t go at
hundred and forty kilometers an hour,
you reduce speed to reduce fuel con-
sumption,” he comments. “This is what
animals had to learn to do during evo-
lution - and they do it at least in part via
the insulin-IGF pathway. The main goal
of this pathway is to adjust growth
rates, or the developmental program in
the case of C. elegans, with respect to
availability of food, and the mechanism
is conserved right down to the level of
the DAF-16 transcription factor.”
Tjian is also excited by the findings.
“We are starting to get a better idea of
how transcription factors affect organ
size and how they are used to decide
when to stop putting new cells into
organs,” he says. And understanding the
role that FOXO plays in morphogenesis
has far-reaching implications in both
the laboratory and medical practice.
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